Form 4: OnKure Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Valerie Malyvanh Jansen, a director of OnKure Therapeutics, acquired stock options for 15,300 shares of Class A Common Stock on October 4, 2024.
Summary
- On October 4, 2024, Valerie Malyvanh Jansen, a director of OnKure Therapeutics, acquired stock options to purchase 15,300 shares of Class A Common Stock at an exercise price of $18.20 per share.
- The options vest monthly, with 1/36th of the shares vesting on November 4, 2024, and each month thereafter, contingent upon continued service.
- Following the transaction, Jansen directly owns options for 15,300 shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, simply reporting a transaction.
Future Outlook
The stock options vest monthly over a three-year period, contingent on the director's continued service with the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the holdings and transactions of company directors. It is common practice for directors to receive stock options as part of their compensation.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 10/04/2024 | Date of stock option transaction |
| 11/04/2024 | First vesting date for the stock options (1/36th of shares) |
| 10/03/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.